OCGN - Ocugen, Inc.
IEX Last Trade
0.7217
-0.393 -54.496%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:18:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$1.12
-0.39
-35.27%
Fundamental analysis
26%
Profitability
35%
Dept financing
19%
Liquidity
42%
Performance
15%
Performance
5 Days
-7.25%
1 Month
-22.12%
3 Months
-29.93%
6 Months
-39.14%
1 Year
59.60%
2 Year
-35.30%
Key data
Stock price
$0.72
DAY RANGE
$0.74 - $1.12
52 WEEK RANGE
$0.52 - $2.10
52 WEEK CHANGE
$33.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Shankar Musunuri
Region: US
Website: ocugen.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ocugen.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis. OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD) and OCU200, is in preclinical development stage.
Recent news